

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
10 February 2022 (10.02.2022)



(10) International Publication Number  
**WO 2022/028572 A1**

(51) International Patent Classification:

C07D 413/14 (2006.01) C07D 405/12 (2006.01)  
C07D 413/00 (2006.01) A61K 31/496 (2006.01)  
C07D 405/14 (2006.01) A61P 3/10 (2006.01)

(21) International Application Number:

PCT/CN2021/111193

(22) International Filing Date:

06 August 2021 (06.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/107437  
06 August 2020 (06.08.2020) CN  
PCT/CN2021/073958  
27 January 2021 (27.01.2021) CN

(71) Applicant: **GASHERBRUM BIO, INC.** [US/US]; 611 Gateway Blvd., Suite 223, South San Francisco, California 94080 (US).

(72) Inventor; and

(71) Applicant (for SC only): **MENG, Qinghua** [CN/CN]; 5th Floor, No. 1 South Bldg., 4560 JinKe Rd., Zhangjiang Hi-Tech Park, Shanghai 201210 (CN).

(72) Inventors: **LEI, Hui**; 5th Floor, No. 1 South Bldg., 4560 JinKe Rd., Zhangjiang Hi-Tech Park, Shanghai 201210 (CN). **ZHANG, Haizhen**; 5th Floor, No. 1 South Bldg., 4560 JinKe Rd., Zhangjiang Hi-Tech Park, Shanghai 201210 (CN). **LIN, Xichen**; 5th Floor, No. 1 South Bldg., 4560 JinKe Rd., Zhangjiang Hi-Tech Park, Shanghai 201210 (CN). **JENNINGS, Andrew**; 611 Gateway Blvd., Suite 223, South San Francisco, California 94080 (US).

(74) Agent: **LINDA LIU & PARTNERS**; F16 Tower C, Beijing Global Trade Center, 36 North Third Ring East Road, Dongcheng District, Beijing 100013 (CN).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: HETEROCYCLIC GLP-1 AGONISTS



(57) Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

WO 2022/028572 A1